NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company’s web site at www.novabaypharma.com.
- 18 years ago
QualityStocks
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
Tags Rodman & Renshaw
Related Post
-
Wild Gold Discovery Drill Holes with Gold Over 200 Meters Intercepts at Lafleur Minerals (CSE: LFLR) (OTCQB: LFLRF) Swanson Gold Deposit Point Towards a District-Scale Gold Discovery
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)and may include paid advertising.…
-
HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions
Cardiovascular disease remains the leading cause of death in the United States. One of the…
-
Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) Positions for Next Phase of Commercial Space Infrastructure Expansion
Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.…